MediXall Group Statistics
Total Valuation
MediXall Group has a market cap or net worth of $130. The enterprise value is $2.82 million.
| Market Cap | 130 |
| Enterprise Value | 2.82M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
MediXall Group has 130.49 million shares outstanding.
| Shares Outstanding | 130.49M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 14.84% |
| Owned by Institutions (%) | n/a |
| Float | 124.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 47.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.00
| Current Ratio | 0.00 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 24.37 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -792.62% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $3,486 |
| Profits Per Employee | -$401,910 |
| Employee Count | 17 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, MediXall Group has paid $2,059 in taxes.
| Income Tax | 2,059 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -100.00% in the last 52 weeks. The beta is -0.48, so MediXall Group's price volatility has been lower than the market average.
| Beta (1Y) | -0.48 |
| 52-Week Price Change | -100.00% |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 0.18 |
| Average Volume (30 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MediXall Group had revenue of $59,268 and -$6.83 million in losses. Loss per share was -$0.06.
| Revenue | 59,268 |
| Gross Profit | -1.61M |
| Operating Income | -6.56M |
| Pretax Income | -6.83M |
| Net Income | -6.83M |
| EBITDA | -6.52M |
| EBIT | -6.56M |
| Loss Per Share | -$0.06 |
Balance Sheet
The company has $3,416 in cash and $2.82 million in debt, giving a net cash position of -$2.82 million or -$0.02 per share.
| Cash & Cash Equivalents | 3,416 |
| Total Debt | 2.82M |
| Net Cash | -2.82M |
| Net Cash Per Share | -$0.02 |
| Equity / Book Value | -3.67M |
| Book Value Per Share | -0.03 |
| Working Capital | -4.33M |
Cash Flow
In the last 12 months, operating cash flow was -$3.56 million and capital expenditures -$3,059, giving a free cash flow of -$3.56 million.
| Operating Cash Flow | -3.56M |
| Capital Expenditures | -3,059 |
| Free Cash Flow | -3.56M |
| FCF Per Share | -$0.03 |
Margins
Gross margin is -2,714.79%, with operating and profit margins of -11,063.71% and -11,528.10%.
| Gross Margin | -2,714.79% |
| Operating Margin | -11,063.71% |
| Pretax Margin | -11,524.63% |
| Profit Margin | -11,528.10% |
| EBITDA Margin | -11,003.45% |
| EBIT Margin | -11,063.71% |
| FCF Margin | -6,013.60% |
Dividends & Yields
MediXall Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.28% |
| Shareholder Yield | -12.28% |
| Earnings Yield | -5,255,749.23% |
| FCF Yield | -2,741,647.69% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 22, 2016. It was a reverse split with a ratio of 1:15.
| Last Split Date | Nov 22, 2016 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
MediXall Group has an Altman Z-Score of -84.03 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -84.03 |
| Piotroski F-Score | 3 |